GKOS Profile
Glaukos Corporation, based in San Clemente, California, is a pioneering ophthalmic medical technology and pharmaceutical company that specializes in developing innovative treatments for glaucoma, corneal disorders, and retinal diseases. Founded in 1998, Glaukos has established itself as a leader in the ophthalmic field by leveraging its expertise in micro-scale device technology to create advanced solutions for vision-related conditions.
The company's flagship products include the iStent, iStent inject, and iStent inject W micro-bypass stents. These devices are designed to enhance aqueous humor outflow and are implanted during cataract surgery to treat mild-to-moderate open-angle glaucoma. These stents represent a significant advancement in minimally invasive glaucoma surgery, providing effective pressure control with a lower risk of complications compared to traditional methods.
Glaukos is also advancing its pipeline with innovative products such as the iStent Infinite and iDose TR. The iStent Infinite is a next-generation three-stent system designed for use as a standalone procedure in patients with refractory glaucoma, offering a new option for those with more severe forms of the disease. The iDose TR is a targeted injectable implant that uses Glaukos' micro-scale device platform to deliver therapeutic levels of medication directly to the eye, aiming to provide sustained and precise drug delivery.
The company distributes its products through a combination of direct sales and a network of distributors both in the United States and internationally. Glaukos’ commitment to advancing ophthalmic care is underscored by its ongoing investment in research and development, aiming to bring new and improved therapies to market. By focusing on novel technologies and patient-centric solutions, Glaukos continues to drive innovation in the treatment of complex eye diseases.
|
